| Literature DB >> 30100187 |
Veronica Rodriguez-Bravo1, Raffaella Pippa2, Won-Min Song3, Marc Carceles-Cordon4, Ana Dominguez-Andres2, Naoto Fujiwara5, Jungreem Woo2, Anna P Koh5, Adam Ertel6, Ravi K Lokareddy7, Alvaro Cuesta-Dominguez8, Rosa S Kim5, Irene Rodriguez-Fernandez4, Peiyao Li9, Ronald Gordon4, Hadassa Hirschfield5, Josep M Prats10, E Premkumar Reddy11, Alessandro Fatatis12, Daniel P Petrylak13, Leonard Gomella14, W Kevin Kelly15, Scott W Lowe16, Karen E Knudsen15, Matthew D Galsky17, Gino Cingolani7, Amaia Lujambio8, Yujin Hoshida5, Josep Domingo-Domenech18.
Abstract
Nuclear pore complexes (NPCs) regulate nuclear-cytoplasmic transport, transcription, and genome integrity in eukaryotic cells. However, their functional roles in cancer remain poorly understood. We interrogated the evolutionary transcriptomic landscape of NPC components, nucleoporins (Nups), from primary to advanced metastatic human prostate cancer (PC). Focused loss-of-function genetic screen of top-upregulated Nups in aggressive PC models identified POM121 as a key contributor to PC aggressiveness. Mechanistically, POM121 promoted PC progression by enhancing importin-dependent nuclear transport of key oncogenic (E2F1, MYC) and PC-specific (AR-GATA2) transcription factors, uncovering a pharmacologically targetable axis that, when inhibited, decreased tumor growth, restored standard therapy efficacy, and improved survival in patient-derived pre-clinical models. Our studies molecularly establish a role of NPCs in PC progression and give a rationale for NPC-regulated nuclear import targeting as a therapeutic strategy for lethal PC. These findings may have implications for understanding how NPC deregulation contributes to the pathogenesis of other tumor types.Entities:
Keywords: E2F1; GATA2; MYC; POM121; androgen receptor; importin β; nuclear import; nuclear pore; nuclear transport; prostate cancer
Mesh:
Substances:
Year: 2018 PMID: 30100187 PMCID: PMC6150493 DOI: 10.1016/j.cell.2018.07.015
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850